Jubilant Therapeutics to Present at Biotech Showcase 2020 on January 13, 2020HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 25 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Jubilant Therapeutics to Present at Biotech Showcase 2020 on January 13, 2020PR NewswireJanuary 10, 2020ReblogShareTweetShareYARDLEY, Pennsylvania, Jan. 10, 2020 /PRNewswire/ -- Jubilant Therapeutics Inc., a patient focused bio-pharmaceutical company focused on addressing unmet needs in Oncology and Auto-immune disorders announced today that Syed Kazmi, President & CEO of Jubilant Therapeutics will present at Biotech Showcase 2020.Jubilant TherapeuticsMoreDate: Monday, January 13, 2020Time: 3:45 p.m. PSTLocation: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San FranciscoTrack: Franciscan B (Ballroom Level)To schedule a meeting with Jubilant Therapeutics during the event, please make a request by email at BD@JubilantTx.comAbout Jubilant Therapeutics Inc.Jubilant Therapeutics is a patient-focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases. Our advanced discovery engine integrates structure-based design and computational architecture to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically defined patient populations. We strive for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Life Sciences' value chain and shared services Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB.The company's lead programs include (1) First-in-class dual epigenetic inhibitor of LSD1/HDAC6 positioned to leverage specific tumor types that are dependent on both these targets, (2) First-in-class PAD4 inhibitor with potential to address unmet needs in multiple auto-immune disorders, (3) Highly selective small molecule PDL-1 inhibitors to improve quality of life with a cost effective therapy in maintenance settings and (4) Selective PRMT5 inhibitors for brain metastases and GBM. For additional information on Jubilant Therapeutics, please visit the company's website at www.jubilanttx.com.CisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/jubilant-therapeutics-to-present-at-biotech-showcase-2020-on-january-13-2020-300984810.htmlSOURCE Jubilant TheraputicsReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextShahs of Sunset's Golnesa 'GG' Gharachedaghi Talks 'Biggest Struggle' of Pregnancy So FarPeopleCalifornia Mom on Autoimmune Disorder That Took Away Her Memory: 'I Didn’t Believe I Had a Child’PeopleBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceWhat the GM strike means for the U.S. economyYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance